Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
3 studies found for:    TMC310911
Show Display Options
Rank Status Study
1 Completed
Has Results
A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients
Condition: Human Immunodeficiency Virus Type 1
Interventions: Drug: TMC310911 75 mg twice daily;   Drug: TMC310911 150 mg twice daily;   Drug: TMC310911 300 mg twice daily;   Drug: TMC310911 300 mg once daily;   Drug: Ritonavir 100 mg twice daily;   Drug: Ritonavir 100 mg once daily
Phase: Phase 2
Sponsor: Tibotec Pharmaceuticals, Ireland
NCT Number: NCT00838162
Study Start: June 2009
Primary Completion: August 2009
2 Completed PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir
Condition: HIV-1
Intervention: Drug: TMC558445; TMC310911; Darunavir; Placebo
Phase: Phase 1
Sponsor: Tibotec Pharmaceuticals, Ireland
NCT Number: NCT00838760
Study Start: February 2009
Primary Completion: October 2009
3 Withdrawn PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.
Condition: HIV Infections
Interventions: Drug: TMC589337 40 mg;   Drug: TMC589337 100 mg;   Drug: TMC589337 200 mg;   Drug: TMC589337 400 mg;   Drug: TMC589354 40 mg;   Drug: TMC589354 100 mg;   Drug: TMC589354 200 mg;   Drug: TMC589354 400 mg;   Drug: TMC589337 AA mg;   Drug: TMC589354 BB mg;   Drug: TMC589337 CC mg;   Drug: TMC589354 DD mg;   Drug: TMC589337 EE mg;   Drug: TMC589354 YY mg;   Drug: TMC310911 300 mg;   Drug: TMC310911 600 mg;   Drug: Placebo
Phase: Phase 1
Sponsor: Tibotec Pharmaceuticals, Ireland
NCT Number: NCT00908414
Study Start: May 2009
Primary Completion: October 2009

Study has passed its completion date and status has not been verified in more than two years.